56621-89-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Methoxypyrimidin-5-amine is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of various medicinal compounds. Its presence in the molecular structure can enhance the pharmacological properties of the final drug products.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Methoxypyrimidin-5-amine is utilized as an intermediate in the production of agrochemicals, helping to create compounds that can improve crop protection and yield.
Used as a Building Block in Organic Synthesis:
2-Methoxypyrimidin-5-amine is used as a building block in the production of various heterocyclic compounds, which are essential in the creation of complex organic molecules with diverse applications in different industries.
Used in Drug Discovery:
Due to its versatility and reactivity, 2-Methoxypyrimidin-5-amine is a valuable chemical for use in drug discovery, where it can be employed to design and develop new pharmaceutical agents with potential therapeutic benefits.

Upstream product

• 14001-69-5 5-nitro-2-methoxypyrimidine 

Downstream Products

• 71119-37-4 sulfanilic acid-(2-methoxy-pyrimidin-5-ylamide) 
• 1253574-90-1 tert-butyl 4-((5-(4-(bis(4-methoxybenzyl)amino)-6-methyl-1,3,5-triazin-2-yl)-6-((2-methoxypyrimidin-5-yl)amino)pyridin-3-yl)methyl)piperazine-1-carboxylate 
• 1253574-91-2 N,N-bis(4-methoxybenzyl)-4-(2-((2-methoxypyrimidin-5-yl)-amino)-5-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-3-yl)-6-methyl-1,3,5-triazin-2-amine 
• 1372927-80-4 (2R,5S)-4-(3-chloro-4-cyanophenyl)-N-(2-methoxypyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide 

Relevant academic research and scientific papers

Catalytic Reductions Without External Hydrogen Gas: Broad Scope Hydrogenations with Tetrahydroxydiboron and a Tertiary Amine

Facile reduction of aryl halides with a combination of 5% Pd/C, B2(OH)4, and 4-methylmorpholine is reported. Aryl bromides, iodides, and chlorides were efficiently reduced. Aryl dihalides containing two different halogen atoms underwent selective reduction: I over Br and Cl, and Br over Cl. Beyond these, aryl triflates were efficiently reduced. This combination was broadly general, effectuating reductions of benzylic halides and ethers, alkenes, alkynes, aldehydes, and azides, as well as for N-Cbz deprotection. A cyano group was unaffected, but a nitro group and a ketone underwent reduction to a low extent. When B2(OD)4 was used for aryl halide reduction, a significant amount of deuteriation occurred. However, H atom incorporation competed and increased in slower reactions. 4-Methylmorpholine was identified as a possible source of H atoms in this, but a combination of only 4-methylmorpholine and Pd/C did not result in reduction. Hydrogen gas has been observed to form with this reagent combination. Experiments aimed at understanding the chemistry led to the proposal of a plausible mechanism and to the identification of N,N-bis(methyl-d3)pyridin-4-amine (DMAP-d6) and B2(OD)4 as an effective combination for full aromatic deuteriation. (Figure presented.).

Photochemical synthesis method of heteroarylamine compounds

The invention provides a photochemical synthesis method of heteroarylamine compounds. The photochemical synthesis method comprises the following steps: S1, mixing raw materials including heteroaryl nitro compounds, a solvent and a photocatalyst to obtain a mixture; and S2, carrying out a photocatalytic reduction reaction on the mixture under an illumination condition to obtain a product system containing the heteroarylamine compounds. According to the photochemical synthesis method, photocatalytic reduction of various different heteroaryl nitro compounds is achieved under the illumination condition, and the high-yield heteroaryl amine compounds are obtained. The photocatalyst is an existing common catalyst, has no strict requirements on equipment and is easy to recover, and the safety riskof the heteroarylamine compound and the catalyst cost are reduced. Any metal reagent and reducing agent do not need to be added in the whole reaction process of photocatalysis, the reaction conversion rate is high, and post-treatment is simple and easy to operate, so the method is safer and more environmentally friendly.

Therapeutically Active Thiazolo-Pyrimidine Derivatives

A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES

A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY

Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.